Neuroleptic malignant syndrome (NMS) requires emergency treatment and can be fatal. Combined aripiprazole and clozapine therapy is rarely used in clinical settings, and NMS related this combination still lacks evaluation. Herein, we present two cases of atypical NMS treated with aripiprazole and clozapine.
Methods
Case 1 was a schizophrenic male with a history of NMS under treatment with aripiprazole 20 mg. He was hospitalized and maintained with aripiprazole 5 mg and clozapine 225 mg. On the 25th day, atypical NMS occurred with rigidity, elevated creatine kinase, and stupor, which subsided with supportive therapy. He was discharged under treatment with aripiprazole 15 mg and fluoxetine 60 mg. Case 2 was a female with schizoaffective disorder without a history of NMS. She was hospitalized and maintained with clozapine 50 mg and aripirazole 30 mg. On the 11th day, atypical NMS occurred with mild fever, delirium, and rigidity, which subsided under supportive therapy.
Results and Conclusions
Our cases highlight the atypical features of NMS in patients being treated with combined ari-piprazole and clozapine. Consciousness change, modest elevation of creatine kinase, and leukocytosis were the most consistent findings; hyperthermia accounts for only some of the cases. This is a reminder of the importance of earlier detection of the soft signs and atypical features of NMS under this combined treatment.
TuralUOnderE. Clinical and pharmacologic risk factors for neuroleptic malignant syndrome and their association with death. Psychiatry and Clinical Neuroscience2010; 64(1): 79–87. doi: 10.1111/j.1440-1819.2009.02042.x.
2.
LazarusAMannSCCaroffSN. The neuroleptic malignant syndrome and related condition, Washington, DC: American Psychiatric Press, 1989.
3.
ViejoLFMoralesVPunalPPerezJLSanchoRA. Risk factors in neuroleptic malignant syndrome. A case-control study. Acta Psychiatrica Scandinavica2003; 107(1): 45–49.
4.
PeloneroALLevensonJLPandurangiAK. Neuroleptic malignant syndrome: A review. Psychiatric Services1998; 49(9): 1163–1172.
5.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 4th. Washington, DC: American Psychiatric Publishing, 2000.
MargeticBAukst-MargeticB. Neuroleptic malignant syndrome and its controversies. Pharmacoepidemiologic Drug Safety2010; 19(5): 429–435. doi: 10.1002/pds.1937.
8.
BhanushaliMJTuitePJ. The evaluation and management ofpatients with neuroleptic malignant syndrome. Neurology Clinics2004; 22(2): 389–411. doi: 10.1016/j.ncl.2003. 12.006.
9.
FriedmanJHFeinbergSSFeldmanRG. A neuroleptic malignantlike syndrome due to levodopa therapy withdrawal. Journal ofthe American Medical Association1985; 254(19): 2792–2795.
10.
SimpsonDMDavisGC. Case report of neuroleptic malignant syndrome associated with withdrawal from amantadine. American Journal of Psychiatry1984; 141(6): 796–797.
11.
Swainston HarrisonTPerryCM. Aripiprazole: A review of its use in schizophrenia and schizoaffective disorder. Drugs2004; 64(15): 1715–1736.
12.
InoueAMikiSSetoMKikuchiTMoritaSUedaHMisuYNakataY. Ari-piprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. European Journal of Pharmacology1997; 321(1): 105–111.
13.
MarderSRMcQuadeRDStockEKaplitaSMarcusRSaffermanAZSahaAAliMIwamotoT. Aripiprazole in the treatment of schizophrenia: Safety and toler-ability inshort-term, placebo-controlled trials. Schizophrenia Research2003; 61(2-3): 123–136.
14.
KarunakaranKTungarazaTEHarborneGC. Is clozapine-aripiprazole combination a useful regime in the management of treatment-resistant schizophrenia?Journal of Psychopharmacology2007; 21(4): 453–456. doi: 10.1177/0269881106068289.
15.
EnglischSZinkM. Combined antipsychotic treatment involving clozapine and aripiprazole. Progress in Neuropsychopharmacologic Biology and Psychiatry2008; 32(6): 1386–1392. doi: 10.1016/j.pnpbp.2008.02.010.
16.
ChangJSAhnYMParkHJLeeKYKimSHKangUGKimYS. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: An 8-week, randomized, double-blind, placebo-controlled trial. Journal of Clinical Psychiatry2008; 69(5): 720–731.
17.
SpaldingSAlessiNERadwanK. Aripiprazole and atypical neuroleptic malignant syndrome. Journal of the American Academy ofChild and Adolescent Psychiatry2004; 43(12): 1457–1458. doi: 10.1097/01.chi.0000142277.95052.94.
18.
SrephichitSSanchezRBourgeoisJA. Neuroleptic malignant syndrome and aripipra-zole in an antipsychotic-naive patient. Journal of Clinical Psychopharmacology2006; 26(1): 94–95.
19.
RodriguezOPDowellMS. A case report of neuroleptic malignant syndrome without fever in a patient given aripiprazole. Journal ofthe Oklahoma State Medical Association2006; 99(7): 435–438.
20.
DassaDDrai-MoogDSamuelianJC. Neuroleptic malignant syndrome with the addition of aripiprazole to clozapine. Progress in Neuropsychopharmacologic Biology and Psychiatry2010; 34(2): 427–428. doi: 10.1016/j.pnpbp.2009.12.022.
21.
TollefsonGDDellvaMAMattlerCAKaneJMWirshingDAKinonBJ. Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group. Journal of Clinical Psychopharmacology1999; 19(5): 435–443.
22.
SachdevPS. A rating scale for neuroleptic malignant syndrome. Psychiatry Research2005; 135(3): 249–256. doi: 0.1016/j.psychres.2005.05.003.
WrenPFrizzellLAKeltnerNLWrightAV. Three potentially fatal adverse effects of psychotropic medications. Perspectives in Psychiatric Care2003; 39(2): 75–81.
25.
AnanthJParameswaranSGunatilakeSBurgoyneKSidhomT. Neuroleptic malignant syndrome and atypical antipsychotic drugs. Journal of Clinical Psychiatry2004; 65(4): 464–470.
26.
SuYPChangCKHayesRDHarrisonSLeeWBroadbentMTaylorDStewartR. Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica2013. doi: 10.1111/ acps.12222.
27.
RialaKLahtiAAnttilaERasanenP. Aripiprazole-related severe neuroleptic malignant syndrome with deep coma and organic brain changes in an antipsychotic-naive adolescent boy. Journal of Clinical Psychopharmacology2013; 33(1): 126–127. doi: 10.1097/01.jcp.0000426179.81948.3f.
28.
ChenYTSuKPChangJP. Early detection and management of atypical neuro-leptic malignant syndrome secondary to aripiprazole. Schizophrenia Research2011; 132(1): 97–98. doi: 10.1016/j.schres.2011.07.005.
29.
FischerVVogelsBMaurerGTynesRE. The antipsychotic clozapine is metabolized by the polymorphic human microsomal and recombinant cytochrome P450 2D6. Journal of Pharmacologic Experimental Therapy1992; 260(3): 1355–1360.
30.
DragovicSGunnessPIngelman-SundbergMVermeulenNPCommandeurJN. Characterization of human cytochrome P450s involved in the bioactivation of clozapine. Drug Metabolism Disposition2013; 41(3): 651–658. doi: 10.1124/dmd.112. 050484.
31.
SpinaEde LeonJ. Metabolic drug interactions with newer antipsychotics: A comparative review. Basic Clinical Pharmacology and Toxicology2007; 100(1): 4–22. doi: 10.1111/j.1742-7843.2007.00017.x.
32.
BursteinESMaJWongSGaoYPhamEKnappAENashNROlssonRDavisREHacksellUWeinerDMBrannMR. Intrinsic efficacy of antipsychotics at human D2, D3, and D4 dopamine receptors: Identification of the clozapine metabolite N-desmethylclozapine as a D2/D3 partial agonist. Journal of Pharmacologic Experimental Therapy2005; 315(3): 1278–1287. doi: 10.1124/jpet.105.092155.
